Connect with us

EU

Investment Plan supports development of therapies for rare genetic diseases

SHARE:

Published

6 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The European Investment Bank (EIB), backed by the European Fund for Strategic Investments (EFSI), will provide €25 million of financing to Minoryx Therapeutics. Minoryx is a biotech company specializing in the advancement of treatments for rare central nervous system disorders. The newly available funding will thus benefit Minoryx's research and development activities in orphan genetic diseases for which there are currently no approved drugs available.

Economy Commissioner Paolo Gentiloni, said: “This EU support will help Minoryx to develop breakthrough therapies for genetic diseases and treatments for diseases of the central nervous system. The coronavirus pandemic has shown how important it is to continue to push scientific boundaries and deliver medication for rare diseases. The European Commission will continue to support companies' efforts in this sense at every opportunity.”

The press release is available here. So far, the Investment Plan for Europe has mobilized €535 billion of investment across the EU, a quarter of which is supporting research, development and innovation projects.

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending